Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab

NCT04884269 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04884269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04884269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
August 11, 2021
Completion date
March 3, 2023
Enrollment
144 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung